The GLP-1 Receptor Agonist Liraglutide Attenuates Atherosclerotic Lesion Development and Potentially Enhances Plaque Stability in an ApoE-/- Mouse Model

被引：0
|
作者：
Simpson, Richard W.
Gaspari, Tracey
Welungoda, Iresha
Widdop, Robert E.
Knudsen, Lotte B.
Dear, Anthony E.
机构：
来源：
DIABETES | 2012年 / 61卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1896-P
引用
收藏
页码：A486 / A486
页数：1
相关论文
共 50 条
  • [31] GLP-1R agonist liraglutide attenuates pain hypersensitivity by stimulating IL-10 release in a nitroglycerin-induced chronic migraine mouse model
    Jing, Feng
    Zou, Qian
    Pu, Yinshuang
    NEUROSCIENCE LETTERS, 2023, 812
  • [32] Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease
    Hansen, Henrik H.
    Fabricius, Katrine
    Barkholt, Pernille
    Kongsbak-Wismann, Pernille
    Schlumberger, Chantal
    Jelsing, Jacob
    Terwel, Dick
    Termont, Annelies
    Pyke, Charles
    Knudsen, Lotte Bjerre
    Vrang, Niels
    PLOS ONE, 2016, 11 (07):
  • [33] Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease
    Tai, Jingjing
    Liu, Weizhen
    Li, Yanwei
    Li, Lin
    Holscher, Christian
    BRAIN RESEARCH, 2018, 1678 : 64 - 74
  • [34] PS1 - 5. The GLP-1 receptor agonist exendin-4 reduces atherosclerosis development and NASH in APOE*3.Leiden.CETP mice
    Edwin T. Parlevliet
    Yanan Wang
    Janine J. Geerling
    Alireza H.M. Jawad
    Veerle Bieghs
    Ronit Shiri-Sverdlov
    Louis M. Havekes
    Johannes A. Romijn
    Patrick C.N. Rensen
    Nederlands Tijdschrift voor Diabetologie, 2012, 10 (3) : 102 - 102
  • [35] The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS
    Amy Keerie
    Heledd Brown-Wright
    Isaac Kirkland
    Andrew Grierson
    James J. P. Alix
    Christian Holscher
    Richard J. Mead
    Scientific Reports, 11
  • [36] A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain
    Cao, Lijun
    Li, Dongfang
    Feng, Peng
    Li, Lin
    Xue, Guo-Fang
    Li, Guanglai
    Holscher, Christian
    NEUROREPORT, 2016, 27 (06) : 384 - 391
  • [37] The GLP-1 receptor agonist, liraglutide, fails to slow disease progression in SOD1G93A and TDP-43Q331K transgenic mouse models of ALS
    Keerie, Amy
    Brown-Wright, Heledd
    Kirkland, Isaac
    Grierson, Andrew
    Alix, James J. P.
    Holscher, Christian
    Mead, Richard J.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [38] Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice
    Jojima, Teruo
    Uchida, Kohsuke
    Akimoto, Kazumi
    Tomotsune, Takanori
    Yanagi, Kazunori
    Iijima, Toshie
    Suzuki, Kunihiro
    Kasai, Kikuo
    Aso, Yoshimasa
    ATHEROSCLEROSIS, 2017, 261 : 44 - 51
  • [39] Grape powder attenuates the negative effects of GLP-1 receptor antagonism by exendin-3 (9-39) in a normoglycemic mouse model
    Haufe, T. C.
    Gilley, A. D.
    Goodrich, K. M.
    Ryan, C. M.
    Smithson, A. T.
    Hulver, M. W.
    Liu, D.
    Neilson, A. P.
    FOOD & FUNCTION, 2016, 7 (06) : 2692 - 2705
  • [40] Early clinical development of the dual GLP-1/glucagon receptor agonist SAR425899 and establishment of a population PK/PD model
    Lindauer, K.
    Goebel, B.
    Tillner, J.
    Posch, M.
    Teichert, L.
    Einig, C.
    Rimbault, M.
    Bergmann, K.
    Keil, S.
    Larsen, P. J.
    Lorenz, M.
    DIABETOLOGIA, 2016, 59 : S57 - S57
12345